Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
- 1 December 2022
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 59, 101036
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyBlood, 2018
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018Cell Death & Differentiation, 2018
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology, 2017
- Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML CellsClinical Cancer Research, 2016
- Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemiaLeukemia Research, 2015
- Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Current Medicinal Chemistry, 2014
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem CellsCell Stem Cell, 2013
- Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaCancer Cell, 2006
- Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapyOncogene, 2006
- Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.Journal of Clinical Investigation, 1990